Experiência clínica com o uso conjunto de sibutramina e orlistat em pacientes obesos

Alfredo Halpern Ana Paola Monegaglia Anna Beatriz G. Oliva Monica Beyruti Zuleika S.C. Halpern Marcio C. Mancini About the authors

The efficacy and tolerability of the association of sibutramine (10mg) and orlistat (120mg t.i.d.) in the treatment of obesity were evaluated in a 3-month short-term open study. The study involved 114 overweight or obese non-diabetic patients searching for obesity treatment in a private clinic. After two months, the mean weight loss was 7.1kg (- 6.5%) and after three months, the mean weight loss was 8.9kg (- 8.2%). The association of sibutramine and orlistat seems to be a useful option for the treatment of obesity.

Sibutramine; Orlistat; Obesity; Treatment of obesity


Sociedade Brasileira de Endocrinologia e Metabologia Rua Botucatu, 572 - conjunto 83, 04023-062 São Paulo, SP, Tel./Fax: (011) 5575-0311 - São Paulo - SP - Brazil
E-mail: abem-editoria@endocrino.org.br